522 related articles for article (PubMed ID: 33854690)
1. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
[TBL] [Abstract][Full Text] [Related]
2. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
3. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
4. The double faced role of xanthine oxidoreductase in cancer.
Chen MM; Meng LH
Acta Pharmacol Sin; 2022 Jul; 43(7):1623-1632. PubMed ID: 34811515
[TBL] [Abstract][Full Text] [Related]
5. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout.
Nishino T; Okamoto K
J Biol Inorg Chem; 2015 Mar; 20(2):195-207. PubMed ID: 25501928
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
8. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
[TBL] [Abstract][Full Text] [Related]
9. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
10. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.
Crawley WT; Jungels CG; Stenmark KR; Fini MA
Redox Biol; 2022 May; 51():102271. PubMed ID: 35228125
[TBL] [Abstract][Full Text] [Related]
11. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Schuchardt M; Herrmann J; Tolle M; van der Giet M
Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
[TBL] [Abstract][Full Text] [Related]
12. Association of Mutations Identified in Xanthinuria with the Function and Inhibition Mechanism of Xanthine Oxidoreductase.
Sekine M; Okamoto K; Ichida K
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829959
[TBL] [Abstract][Full Text] [Related]
13. The treatment of hyperuricemia.
Gliozzi M; Malara N; Muscoli S; Mollace V
Int J Cardiol; 2016 Jun; 213():23-7. PubMed ID: 26320372
[TBL] [Abstract][Full Text] [Related]
14. Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.
Wang H; Xie L; Song X; Wang J; Li X; Lin Z; Su T; Liang B; Huang D
Front Immunol; 2022; 13():773001. PubMed ID: 35154100
[TBL] [Abstract][Full Text] [Related]
15. Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease.
Shimizu M; Naito R; Sato A; Ishiwata S; Yatsu S; Shitara J; Matsumoto H; Murata A; Kato T; Suda S; Hiki M; Kuwabara M; Murase T; Nakamura T; Kasai T
Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892555
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of hypoxanthine and xanthine by obesity in a general population.
Furuhashi M; Koyama M; Higashiura Y; Murase T; Nakamura T; Matsumoto M; Sakai A; Ohnishi H; Tanaka M; Saitoh S; Moniwa N; Shimamoto K; Miura T
J Diabetes Investig; 2020 Jul; 11(4):878-887. PubMed ID: 31916414
[TBL] [Abstract][Full Text] [Related]
17. Xanthine Oxidoreductase Inhibitors.
Vickneson K; George J
Handb Exp Pharmacol; 2021; 264():205-228. PubMed ID: 32789757
[TBL] [Abstract][Full Text] [Related]
18. Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity.
Niu Y; Li H; Gao L; Lin H; Kung H; Lin MC; Leung KS; Wong MH; Xiong W; Li L
J Pharmacol Sci; 2017 Nov; 135(3):114-120. PubMed ID: 29132796
[TBL] [Abstract][Full Text] [Related]
19. Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.
Furuhashi M; Higashiura Y; Koyama M; Tanaka M; Murase T; Nakamura T; Akari S; Sakai A; Mori K; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Hypertens Res; 2021 Sep; 44(9):1213-1220. PubMed ID: 34117403
[TBL] [Abstract][Full Text] [Related]
20. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
Battelli MG; Polito L; Bolognesi A
Atherosclerosis; 2014 Dec; 237(2):562-7. PubMed ID: 25463089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
